NZ200309A - Prostaglandin compositions stabilised with acetals - Google Patents

Prostaglandin compositions stabilised with acetals

Info

Publication number
NZ200309A
NZ200309A NZ200309A NZ20030982A NZ200309A NZ 200309 A NZ200309 A NZ 200309A NZ 200309 A NZ200309 A NZ 200309A NZ 20030982 A NZ20030982 A NZ 20030982A NZ 200309 A NZ200309 A NZ 200309A
Authority
NZ
New Zealand
Prior art keywords
acetal
prostaglandin
amount
present
water
Prior art date
Application number
NZ200309A
Other languages
English (en)
Inventor
C-D Yu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of NZ200309A publication Critical patent/NZ200309A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ200309A 1981-04-16 1982-04-15 Prostaglandin compositions stabilised with acetals NZ200309A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/254,824 US4358603A (en) 1981-04-16 1981-04-16 Acetal stabilized prostaglandin compositions

Publications (1)

Publication Number Publication Date
NZ200309A true NZ200309A (en) 1985-03-20

Family

ID=22965721

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ200309A NZ200309A (en) 1981-04-16 1982-04-15 Prostaglandin compositions stabilised with acetals

Country Status (12)

Country Link
US (1) US4358603A (enExample)
EP (1) EP0063367B1 (enExample)
JP (1) JPS57181054A (enExample)
AT (1) ATE9061T1 (enExample)
AU (1) AU553104B2 (enExample)
CA (1) CA1168155A (enExample)
DE (1) DE3260600D1 (enExample)
HK (1) HK43987A (enExample)
IE (1) IE52854B1 (enExample)
MY (1) MY8700597A (enExample)
NZ (1) NZ200309A (enExample)
ZA (1) ZA822578B (enExample)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0668076B1 (en) * 1992-08-26 2002-09-04 Sucampo AG Stabilization of a prostanoic acid compound
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6432994B1 (en) 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
US7169410B1 (en) * 1998-05-19 2007-01-30 Sdg, Inc. Targeted liposomal drug delivery system
AU1624801A (en) 1999-11-19 2001-05-30 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US20050065118A1 (en) * 2001-10-16 2005-03-24 Jing Wang Organosulfur inhibitors of tyrosine phosphatases
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US6696473B2 (en) * 2001-12-21 2004-02-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
EP1521746B1 (en) 2002-03-07 2011-04-27 X-Ceptor Therapeutics, Inc. Quinazolinone modulators of nuclear receptors
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003248747A1 (en) 2002-06-27 2004-01-19 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
AU2004251668B2 (en) * 2003-06-03 2008-03-20 Triad Therapeutics, Inc 5-membered heterocycle-based p-38 inhibitors
EP1911754B1 (en) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050203184A1 (en) * 2003-09-10 2005-09-15 Petasis Nicos A. Benzo lipoxin analogues
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
JP2007538103A (ja) 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
EP1765332A2 (en) * 2004-06-17 2007-03-28 Cengent Therapeutics, Inc. Trisubstituted nitrogen modulators of tyrosine phosphatases
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
BRPI0513310A (pt) 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ588432A (en) 2004-09-17 2012-03-30 Whitehead Biomedical Inst Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
CA2637275C (en) 2006-01-24 2014-12-09 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
EP2007373A4 (en) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
EP2079696A2 (en) 2006-10-09 2009-07-22 Takeda San Diego, Inc. Kinase inhibitors
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP2113500A1 (en) 2006-10-31 2009-11-04 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CA2706465A1 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
JP5539221B2 (ja) 2007-12-21 2014-07-02 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的アンドロゲン受容体モジュレーター(sarm)およびその使用
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
EP2311842A3 (en) 2008-06-24 2011-07-13 Takeda Pharmaceutical Company Limited PI3K/M TOR inhibitors
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
CA3050530A1 (en) 2009-01-06 2010-07-15 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
JP2012514604A (ja) 2009-01-06 2012-06-28 キュレロン リミテッド ライアビリティ カンパニー 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
EP2415767B1 (en) 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
JP5715625B2 (ja) 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ(adp−リボース)ポリメラーゼ(parp)阻害剤
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
EP2515654A4 (en) * 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
EP2585455B1 (en) 2010-06-24 2019-08-07 The Regents of the University of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
MX362974B (es) 2011-04-21 2019-02-28 Curemark Llc Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
EP2723735A4 (en) 2011-06-23 2015-02-18 Map Pharmaceuticals Inc NOVEL ANALOGUES OF FLUORO-ERGOLINE
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
AU2012355982A1 (en) 2011-12-19 2014-07-10 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
US8946420B2 (en) 2011-12-21 2015-02-03 Map Pharmaceuticals, Inc. Neuromodulatory compounds
IN2012DE00661A (enExample) 2012-03-07 2015-08-21 Univ Delhi
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US8551535B1 (en) 2012-08-06 2013-10-08 Sarah McCann Homeopathic remedies and methods for enhancing weight loss
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
CA2895829A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
CA2902232C (en) 2013-02-22 2020-12-29 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
AU2014233185B2 (en) 2013-03-15 2018-03-15 University Of Southern California Methods, compounds, and compositions for the treatment of angiotensin-related diseases
SG10201708143QA (en) 2013-06-06 2017-11-29 Pf Medicament Anti-c10orf54 antibodies and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
WO2016070107A1 (en) 2014-10-31 2016-05-06 The General Hospital Corporation Potent gamma-secretase modulators
WO2016094837A2 (en) 2014-12-11 2016-06-16 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
KR102740384B1 (ko) 2015-03-03 2024-12-06 키맵 리미티드 항체, 용도 및 방법
EP3289104B1 (en) 2015-04-29 2020-11-04 New York University Method for treating high-grade gliomas
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP4455145A3 (en) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl nociceptin receptor compounds
CN109153642B (zh) 2016-02-12 2022-05-17 法玛西斯有限公司 赖氨酰氧化酶的吲哚及氮杂吲哚卤化烯丙胺衍生物抑制剂及其用途
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
WO2017156183A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
US10064855B2 (en) 2016-03-08 2018-09-04 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
EP4190357A1 (en) 2016-05-13 2023-06-07 Institut Pasteur Inhibition of beta-2 nicotinic acetylcholine receptors to treat alzheimer's disease pathology
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
CN116730920A (zh) 2017-02-17 2023-09-12 文涵治疗有限公司 Ag-10的制备方法、其中间体及其盐
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
JP2020522504A (ja) 2017-06-01 2020-07-30 エックスオーシー ファーマシューティカルズ インコーポレイテッドXoc Pharmaceuticals, Inc 多環式化合物およびそれらの用途
ES2953032T3 (es) 2017-09-01 2023-11-07 Univ East Carolina Métodos ex vivo para la activación de las células inmunológicas
WO2019099353A1 (en) 2017-11-15 2019-05-23 California State University Northridge Compositions and methods for the treatment and prevention of cancer
MA52137A (fr) 2018-03-23 2021-01-27 Eidos Therapeutics Inc Méthodes de traitement de l'amylose ttr à l'aide d'ag10
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
CA3105599A1 (en) 2018-08-03 2020-02-06 Pharmaxis Ltd. Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof
AU2019321583C1 (en) 2018-08-17 2025-11-27 Eidos Therapeutics, Inc. Formulations of AG10
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
TWI839461B (zh) 2019-02-06 2024-04-21 美商戴斯阿爾法股份有限公司 Il-17a調節物及其用途
KR20220003554A (ko) 2019-04-19 2022-01-10 리간드 파마슈티칼스 인코포레이티드 화합물의 결정질 형태 및 결정질 형태를 제조하는 방법
JP7754724B2 (ja) 2019-05-20 2025-10-15 ニルバナ サイエンシーズ インク. 発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
CN114222802B (zh) 2019-05-20 2025-07-11 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
JP7566889B2 (ja) 2019-09-16 2024-10-15 ダイス・アルファ・インコーポレイテッド Il-17aモジュレーターおよびその使用
EP4149471A4 (en) 2020-06-30 2024-07-10 Prosetta Biosciences, Inc. ISOQUINOLINE DERIVATIVES, PROCESSES FOR THE SYNTHESIS AND USES THEREOF
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
IL305752A (en) 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
AU2022368836A1 (en) 2021-10-22 2024-05-02 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
JP2025501308A (ja) 2022-01-03 2025-01-17 ライラック セラピューティクス, インク. 非環式チオールプロドラッグ
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー, インク. ニコチン酸及びリボースから誘導体化した新規プロドラッグ
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749800A (en) * 1971-11-01 1973-07-31 Upjohn Co Stable composition for dispensing pge2
US3833612A (en) * 1971-11-24 1974-09-03 Merck & Co Inc Derivatives of 5-oxo-1 beta-cyclopentane-heptanoic acid,5-ethylene acetals
US4178457A (en) * 1978-07-10 1979-12-11 Syntex (U.S.A.) Inc. (dl)-16-Phenoxy- and 16-substituted phenoxy-9-keto prostatrienoic acid derivatives and processes for the production thereof
US4178454A (en) * 1978-10-11 1979-12-11 Toray Industries, Inc. Stabilized prostaglandin E composition

Also Published As

Publication number Publication date
ATE9061T1 (de) 1984-09-15
IE820889L (en) 1982-10-16
EP0063367B1 (en) 1984-08-22
IE52854B1 (en) 1988-03-30
JPH0219805B2 (enExample) 1990-05-07
HK43987A (en) 1987-06-12
DE3260600D1 (en) 1984-09-27
AU8263582A (en) 1982-10-21
US4358603A (en) 1982-11-09
JPS57181054A (en) 1982-11-08
ZA822578B (en) 1983-11-30
EP0063367A1 (en) 1982-10-27
CA1168155A (en) 1984-05-29
AU553104B2 (en) 1986-07-03
MY8700597A (en) 1987-12-31

Similar Documents

Publication Publication Date Title
US4358603A (en) Acetal stabilized prostaglandin compositions
CA1187797A (en) Carbonate diester solutions of pge-type compounds
CA1203172A (en) Propylene glycol diester solutions of pge-type compounds
US4410545A (en) Carbonate diester solutions of PGE-type compounds
CA1176567A (en) Pharmaceutical preparation
JPH0720861B2 (ja) 心臓障害の処置または予防用の医薬組成物および方法
US4784855A (en) Pharmaceutical compositions and suppository
CA1134820A (en) Triethyl citrate solutions of pge-type compounds
US6949526B2 (en) Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
TWI403324B (zh) 醫藥組成物
US4389414A (en) Prostaglandin compositions
US4301175A (en) E-Type prostaglandin compositions
US4296131A (en) Pharmaceutical compositions and their use in the prophylaxis and/or treatment of certain diseases
US6710081B1 (en) Erection insufficiency remedies
CA1282703C (en) Stable injectable antiemetic compositions
JPH0478612B2 (enExample)
US4882356A (en) Stable injectable antiemetic compositions
JPS629091B2 (enExample)